NEUROCRINE BIOSCIENCES INC (1NBIX.MI) Stock Price, Forecast & Analysis
Europe - Euronext Milan - BIT:1NBIX - US64125C1099 - Common Stock
1NBIX.MI Key Statistics, Chart & Performance
The current stock price of 1NBIX.MI is 131.55 EUR.
1NBIX.MI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1AE.DE | ARGENX SE | 68.21 | 44.30B | ||
| ARGX.BR | ARGENX SE | 68.11 | 44.24B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 18.82B | ||
| ABVX.PA | ABIVAX SA | N/A | 9.50B | ||
| 2X1.DE | ABIVAX SA | N/A | 9.31B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.84B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.84B | ||
| NANO.PA | NANOBIOTIX | N/A | 950.81M | ||
| 5CV.DE | CUREVAC NV | 6.1 | 796.20M | ||
| IVA.PA | INVENTIVA SA | N/A | 718.23M | ||
| PHIL.MI | PHILOGEN SPA | 20.53 | 684.22M | ||
| FYB.DE | FORMYCON AG | N/A | 439.10M |
Related stock screener links
About 1NBIX.MI
Company Profile
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company is headquartered in San Diego, California and currently employs 1,800 full-time employees. The firm is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa, and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.
Company Info
NEUROCRINE BIOSCIENCES INC
6027 Edgewood Bend Court
San Diego CALIFORNIA US
Employees: 1800
Phone: 18586177600
NEUROCRINE BIOSCIENCES INC / 1NBIX.MI FAQ
What does 1NBIX do?
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company is headquartered in San Diego, California and currently employs 1,800 full-time employees. The firm is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa, and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.
What is the stock price of NEUROCRINE BIOSCIENCES INC today?
The current stock price of 1NBIX.MI is 131.55 EUR. The price increased by 4.9% in the last trading session.
Does NEUROCRINE BIOSCIENCES INC pay dividends?
1NBIX.MI does not pay a dividend.
What is the ChartMill rating of NEUROCRINE BIOSCIENCES INC stock?
1NBIX.MI has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
What sector and industry does NEUROCRINE BIOSCIENCES INC belong to?
NEUROCRINE BIOSCIENCES INC (1NBIX.MI) operates in the Health Care sector and the Biotechnology industry.
Can you provide the growth outlook for NEUROCRINE BIOSCIENCES INC?
The Revenue of NEUROCRINE BIOSCIENCES INC (1NBIX.MI) is expected to grow by 21.48% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the employee count for 1NBIX stock?
NEUROCRINE BIOSCIENCES INC (1NBIX.MI) currently has 1800 employees.
1NBIX.MI Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to 1NBIX.MI.
1NBIX.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to 1NBIX.MI. 1NBIX.MI scores excellent points on both the profitability and health parts. This is a solid base for a good stock.
1NBIX.MI Financial Highlights
Over the last trailing twelve months 1NBIX.MI reported a non-GAAP Earnings per Share(EPS) of 3.55. The EPS increased by 12.06% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 15.95% | ||
| ROA | 10.03% | ||
| ROE | 14.25% | ||
| Debt/Equity | 0 |
1NBIX.MI Forecast & Estimates
For the next year, analysts expect an EPS growth of 53.46% and a revenue growth 21.48% for 1NBIX.MI